Review of applications of CRISPR-Cas9 gene-editing technology in cancer research

Zhao, Ziyi; Li, Chenxi; Tong, Fei; Deng, Jingkuang; Huang, Guofu; Sang, Yi

doi:10.1186/s12575-021-00151-x

Cited by 23 publications

(14 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study further investigated whether cell migration and invasion were significantly reduced by the downregulation of TRIM11 expression in NPC cells. CRISPR-Cas9 gene-editing technology has attracted great interest in cancer research since it promotes the exploration of molecular mechanisms underlying cancer progression and the development of accurate treatment [ 14 ]. CRISPR/Cas9 gene editing was used to construct stable TRIM11-knockdown cell lines.…”

Section: Resultsmentioning

confidence: 99%

TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells

Zhao

Deng

et al. 2022

Mol Biol Rep

Self Cite

View full text Add to dashboard Cite

Background Although tripartite motif-containing protein 11 (TRIM11) is known to be associated with a variety of cancers, its role in nasopharyngeal carcinoma (NPC) is unclear. Methods and results To investigate the role of TRIM11 in NPC, TRIM11 was stably overexpressed in 6–10B and CNE2 cells with lentiviral vectors and knocked down in S18 and 5–8F cells using the CRISPR/Cas9 system. Transwell assays and wound-healing assays revealed that TRIM11 facilitated the migration and invasion of NPC cells. Mechanistically, we found that p53 inhibits TRIM11 expression by binding to its promoter. Conclusions TRIM11 may serve as a potential diagnostic marker for NPC and has a certain therapeutic value.

show abstract

Section: Resultsmentioning

confidence: 99%

TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells

Zhao

Deng

et al. 2022

Mol Biol Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is possible to target blood disorders and cancer with CRISPR/Cas9. It is possible to edit cells removed from patients in the laboratory and then reintroduce the modified cells back into the patient [ 49 ]. Blood disorders and cancer are other diseases that can be treated.…”

Section: Methodsmentioning

confidence: 99%

A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma

AMJAD,

PEZZANI,

SOKOUTI

2024

View full text Add to dashboard Cite

Noncoding RNAs instruct the Cas9 nuclease to site-specifically cleave DNA in the CRISPR/Cas9 system. Despite the high incidence of hepatocellular carcinoma (HCC), the patient’s outcome is poor. As a result of the emergence of therapeutic resistance in HCC patients, clinicians have faced difficulties in treating such tumor. In addition, CRISPR/Cas9 screens were used to identify genes that improve the clinical response of HCC patients. It is the objective of this article to summarize the current understanding of the use of the CRISPR/Cas9 system for the treatment of cancer, with a particular emphasis on HCC as part of the current state of knowledge. Thus, in order to locate recent developments in oncology research, we examined both the Scopus database and the PubMed database. The ability to selectively interfere with gene expression in combinatorial CRISPR/Cas9 screening can lead to the discovery of new effective HCC treatment regimens by combining clinically approved drugs. Drug resistance can be overcome with the help of the CRISPR/Cas9 system. HCC signature genes and resistance to treatment have been uncovered by genome-scale CRISPR activation screening, although this method is not without limitations. It has been extensively examined whether CRISPR can be used as a tool for disease research and gene therapy. CRISPR and its applications to tumor research, particularly in HCC, are examined in this study through a review of the literature.

show abstract

“…During the last two decades gene editing, especially CRISPR/Cas9-mediated, has been successfully applied in both animal and plant systems. High expectations in medicine are connected with CRISPR/Cas9-mediated gene therapy (Zhang 2021), cancer treatment (Zhao et al 2021), xenotransplantology (Ryczek et al 2021), and with development of new, more effective drugs and vaccines (Scott 2018). Gene-specific mutation technology is used to produce improved industrial enzymes for waste processing into fuels, thus contributing to the reduction of environmental pollution and alleviating the energy crisis (Zhu et al 2022).…”

Section: Site-directed Mutagenesismentioning

confidence: 99%

Site-Directed Mutagenesis – A Chance to Meet Environmental Challenges and Provide Healthy Food for People or an Unacceptable Hazard to Humans, Animals, and the Environment. Consequences of the European Court of Justice Judgment in Case C-528/16

Michalczuk

2022

Journal of Horticultural Research

View full text Add to dashboard Cite

One of the EU's strategic goals is to reduce the environmental and climate footprint of the EU food system and strengthen its resilience, while ensuring food security for European citizens. Thus, the EU Farm to Fork strategy, which is one of the central pillars of the European Green Deal, set ambitious targets for 2030 to reduce pesticide use in agriculture by 50% and fertilizers use by 20%, with a concomitant 50% reduction of nutrient leakage to surface and groundwater. Additionally, it is recommended that at least 25% of the EU agricultural land shall be kept under organic farming. These goals are far-reaching, but several recent studies indicate that implementing them without significant progress in research and innovation (R & I) may result in a yield decrease by up to 30%, depending on the crop, and an increase in the price of agricultural commodities by up to 18%. Especially affected would be horticulture due to its high dependence on plant protection against pests and diseases. Therefore, the studies recommend accelerating plant breeding in order to produce new plant cultivars genetically resistant to pests and diseases and better equipped to cope with abiotic stresses like limited nutrition and water deficit. The progress in classical plant breeding is a lengthy process. It is especially slow in the case of woody species, like most fruit plants, due to their long juvenile periods and limited genetic variance. Recent advances in functional genomics, bioinformatics, and molecular methods provided tools that speed up the breeding process significantly. Several site-directed mutation technologies allow modifying a specific gene at a predefined site, by deletion or insertion of single or multiple nucleotides, without affecting off-target genes. Several valuable cultivars have been bred so far using these methods, and a large number of others are under trials. However, their release will be severely impeded by the decision of the Court of Justice of the European Union, dated 25 July 2018, that the release of organisms obtained by site-specific mutations, as opposed to organisms obtained by induced random mutation, is controlled by Directive 2001/18/EC2 on genetically modified organisms. This paper reviews the new generation breeding techniques, especially site-directed mutagenesis, and their benefits as well as potential hazards to consumers and the environment.

show abstract

Review of applications of CRISPR-Cas9 gene-editing technology in cancer research

Cited by 23 publications

References 107 publications

TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells

TRIM11, a new target of p53, facilitates the migration and invasion of nasopharyngeal carcinoma cells

A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma

Site-Directed Mutagenesis – A Chance to Meet Environmental Challenges and Provide Healthy Food for People or an Unacceptable Hazard to Humans, Animals, and the Environment. Consequences of the European Court of Justice Judgment in Case C-528/16

Contact Info

Product

Resources

About